Sep 10 2008
British NICE did not say to four kind of kidney cancer medicine
The British country health Service organization (country medical system cost - titre monitor organization) said that the kidney cancer patient should not use four expensive new medicines.
the Britain State-run Clinical Standard Research institute (NICE) said that Roche company’s Avastin (bevacizumab, not yet in the Chinese going on the market), Baier Corporation’s Zola non-Nepal (the Dorje US, already went on the market in China, uses in treating later period kidney cancer and liver cancer), Huirui Corporation’s Shu Ni Tini (rope Tanzania, already went on the market in China, uses in treating later period kidney cancer and stomach and intestines mesenchymoma) as well as Wyeth Corporation carries on the back Swiss Sayre (Torisel, not yet in the Chinese going on the market).
although these four medicines may lengthen the patient life several months, but the performance-to-price ratio is not high. NICE said in theirs preliminary recommendation, therefore these medicines should not be the progress time and/or the transferability kidney cancer’s treatment choice. This decision has solved NICE adopts the medical service classification regarding England and Wales the contradiction, rejects these in many national convention use expensive new medicine, particularly in the US. the Britain cancer studied said whether the NICE examination system did suit regarding all type’s medicine, still existed argued, when particularly did not have treatment time which anything might substitute. NICE said that which medicine should spend in the decision for, should not which medicine spends for, must make the difficult choice. the new research and development’s target is innovating cancer to the medicine to treat, but can only lengthen frequently the life several months. The drugs company said that they must adopt the high charge, with the aim of taking back their high risk the research investment. the NICE computation said that the kidney cancer pharmacological treatment price is expensive, means increases one year life every time, needs to spend 71500 to 171300 pounds. Since 1999, NICE has occupied the world leading position in the appraisal medicine’s performance-to-price ratio, but along with other national taxpayer hoped that finds the reasonable method, appraises the new target to treat the medicine to cancer to spend reasonably, the similar health technical appraisal is whether prosperous.